The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Cannabis Intoxication

In brief

This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act to help with detection of driving under the influence of cannabis. One hundred and eighty healthy volunteers will inhale smoked cannabis with either 0% (placebo), 5.9%, or 13.4% Δ9-tetrahydrocannabinol (THC) at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and a number of times over the subsequent 6 hours after cannabis smoking. The purpose is to determine (1) the relationship of the dose of Δ9-THC on driving performance and (2) the duration of driving impairment in terms of hours from initial use, (3) if saliva or expired air can serve as a useful substitute for blood sampling of Δ9-THC, and (4) if testing using an iPad can serve as a useful adjunct to the standardized field sobriety test in identifying acute impairment from cannabis.

Key facts

Study ID

NCT02849587

Run by

University of California, San Diego

People needed

199

Starts

2017-02-24

Expected to finish

2019-06-17

Last updated by the study team

2022-01-04

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Be a licensed driver.
• Need to have acuity of 20/40 or better, with or without correction on a Snellen Visual Acuity eye chart.

You may not qualify if…

• At the discretion of the examining physician, individuals with significant cardiovascular, hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (eg, asthma, COPD) will be excluded.
• Unwillingness to abstain from cannabis for 2 days prior to screening and experimental visits
• Positive pregnancy test
• A positive result on toxicity screening for cocaine, amphetamines, opiates, and phencyclidine (PCP) will exclude individuals from participation.
• Unwilling to refrain from driving or operating heavy machinery for four hours after consuming study medication.

Where it is running

• Center for Medicinal Cannabis Research, UC San Diego — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.